I86th I-China International Pharmaceutical Raw Materials/I-Intermediates/Packaging/Equipment Fair (API China ngokufutshane)

Umququzeleli: iReed Sinopharm Exhibition Co., Ltd.

Ixesha lomboniso: Meyi 26-28, 2021

Indawo: Indawo yaseTshayina yokuNgenisa nokuThumela ngaphandle kweFayile Complex (eGuangzhou)

Isikali somboniso: 60,000 square metres

Ababonisi: 1500+

Inombolo yabaphulaphuli: 60000+

Thina,Changzhou Pharmaceutiacl Factoryephethwe yiShanghai Pharma.,iya kuzimasayena China Import and Export Fair Complex (Guangzhou)e 10.2M15 kuba tyena 86th China International Pharmaceutical Raw Materials/Intermediates/Packaging/Equipment Fair (API China ngokufutshane)

Kwiminyaka yakutshanje, ilizwe lam liye lakhupha ngokulandelelana uthotho lwemigaqo-nkqubo yokukhuthaza nokuxhasa uphuhliso lweshishini lebiomedical. Kulo mongo, ishishini le-biopharmaceutical nalo liqalise ukungena kwinqanaba lophuhliso olukhawulezayo, kwaye libonise ukukhula okunamandla okukhulayo. Okwangoku, izinga lokukhula kwayo kwimarike sele liqalisile ukudlula kancinci imeko yonke yentengiso yamayeza. Ngokwengxelo yeFrost & Sullivan, ngo-2019, imakethi yaseTshayina ye-biopharmaceutical yafikelela kwi-317.2 yeebhiliyoni zeeyuan. Ngokunyuka kokufikeleleka, ukukhula kwezigulana kunye nokwandiswa kwe-inshurensi yezonyango, imakethi ye-biopharmaceutical kulindeleke ukuba ifikelele kwi-464.4 yeebhiliyoni zeeyuan ngo-2021.

Ke, phambi kwamathemba amakhulu emarike, yeyiphi eyona migca iphambili yotyalo-mali kumzi mveliso we-biopharmaceutical efanele ukuhoywa ngo-2021? Ngokutsho kweshishini, ngokusekwe kwi-pullback yamva nje yecandelo lamachiza, kucetyiswa ukuba ubeke ingqalelo kwimigca emithathu yotyalo-mali ephambili phantsi kwendlela eqhelekileyo yokuphuculwa kwamashishini.:

一.Amashishini amatsha akumgangatho ophezulu anokhuphiswano lwehlabathi

Iyeza lihlala lishishini lokuphuma kwelanga kunye nophuhliso olunamandla. Nangona kunjalo, phantsi kwemvelaphi yokuba ishishini lamachiza lingena kuphuhliso oluphezulu kwaye imboni ikhawuleza inguqu yayo, ukuphuhliswa kwamachiza amatsha kwiinkampani zamachiza ngundoqo ekusombululeni iimfuno zeklinikhi ezingafezekanga, ukugcinwa kunye nokukhuphisana. 

Okwangoku, ngokwembono yehlabathi, iinkampani ezinkulu ezixuba amayeza zonke ziinkampani zamachiza ezenza izinto ezintsha. Ngokomzekelo, ixabiso lemarike likaJohnson & Johnson, elinamayeza kunye nezixhobo, liphezulu njenge-374.5 yeebhiliyoni zeedola zase-US, kwaye ixabiso lemarike yeenkampani eziphezulu zamachiza ezifana ne-Roche kunye ne-Pfizer nazo zingaphezu kwe-100 yeebhiliyoni zeedola zase-US; kodwa njengoko iTeva Pharmaceuticals, enye yeenkampani ezinkulu zehlabathi zamachiza enziwe afana nalawo aveliswe ngumenzi, inexabiso lemarike le-$12.3 yeebhiliyoni kuphela. Inokubonwa koku kungasentla ukuba ukuveliswa kwezinto ezintsha kuye kwaba yinto enamandla yokuqhubela phambili uphuhliso olungcono loshishino lwebhayoloji kunye namashishini.

Kuyafaneleka ukuba siqaphele ukuba ukuba sifuna ukuba neemarike ezininzi, akwanele ukuthembela kwimarike yasekhaya kuphela. Kuphela ngokutyhala amachiza akhuphisanayo kumazwe ngamazwe phesheya kunye nokuthatha inxaxheba kukhuphiswano kwimarike yehlabathi enesithuba esithe chatha apho sinokuthi sibe nethuba lokufumana imbuyekezo engcono. . Ke ngoko, ishishini ngokubanzi likholelwa ukuba iinkampani ezivelisa izinto ezintsha ezikumgangatho ophezulu ezinokhuphiswano lwehlabathi zinamathuba amaninzi ophuhliso. Kunconywa ukuba ubeke ingqalelo kwiinkampani ezivelisa amayeza eziye zaseka amajelo okuthengisa ngokuthe ngqo phesheya.

二.Enxulumene nee-DRGs” icandelo labaxhamli

Ngo-2021, intlawulo eyiyo ye-DRGs iya kuqala, eya kuba nefuthe elibi kakhulu ekuxilongweni kweklinikhi kunye nonyango, iifizi zokulawula i-inshorensi yezonyango, njl. ukusetyenziswa kwamanye amayeza anexabiso eliphezulu, nakumachiza ophando lokuqala, iinkampani ezixuba amayeza ezifanelekileyo ziyakufumana umonakalo omkhulu ukuba aziguquki ngexesha.

Nangona kunjalo, nangona amanye amachiza kunye neenkampani ziya kuba nemingeni kakhulu. Nangona kunjalo, ishishini liqikelela ukuba iintlobo zeziyobisi ezineempawu zokusetyenziswa ngamandla, iziyobisi ezingxamisekileyo, unyango lwenqanaba lokugqibela kunye neziyobisi eziphuma ngaphandle azinakuchaphazeleka, kwaye phantsi kovavanyo lweendleko-inzuzo, iya kukhuthaza ukwanda kwenqanaba lokungena kwe-ICL kunye nokungenisa. endaweni yoshishino lwe-IVD. Ukongeza, izixhobo ezingundoqo ezinyukayo (izinto ezisetyenziswayo kunye nezixhobo, ii-API ezinelungelo lobunikazi) nazo zinokuzuza kule nto. Kunconywa ukuba ubeke ingqalelo kwi: WuXi Biologics, Tofflon, Kailai Ying kunye nezinye iinkampani.

三.Ukuphumelela kakhulu kweR&D indawo yokukhupha iziyobisi

Phantsi kweempembelelo zezinto ezifana nokunyuka ngokubanzi kutyalo-mali lweR&D lwamayeza ehlabathi kunye nemigaqo-nkqubo encomekayo yasekhaya, yimvumelwano kushishino ukuba imarike yenkonzo yeR&D yokukhutshwa kweziyobisi (okt. CXO), eyinxalenye ebalulekileyo yekhonkco leshishini lamachiza, liza kwenza izinto ezintsha. luncedo ngokucacileyo.

Abangaphakathi kwimizi-mveliso bakholelwa ekubeni abaqalisi ngoku ngokuthe ngcembe baba ngamandla aphambili kuphando kunye nophuhliso lwamachiza amatsha kushishino lwebhayoloji. Nangona kunjalo, ngenxa yokunqongophala kweetalente, inkxaso-mali, kunye nendawo, abaqalisi bahlala belungelelanisa abasebenzi kwaye balandele ukusebenza kakuhle kunye neendleko eziphantsi. Ngoko ke, baxhomekeke kwiinkampani zeCXO. Ithande ukuba phezulu. Kuyaqondwa ukuba inkampani edwelisiweyo yeCMO ithe ngenxa yezi zizathu zingasentla, inani leenkampani zamachiza e-bio-innovative kwintsebenzo yeenkampani zeCXO liye landa ngokuthe ngcembe kwiminyaka yakutshanje, kwaye liba ngumthombo obalulekileyo wegalelo. ekukhuleni kwengeniso yenkampani yeCXO kunye nenzuzo.